via Neuroscience News
James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Cdk5 is a crucial regulator of signaling in brain neurons. Over three decades of study, it has been implicated in neuropsychiatric and neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. Knocking out the enzyme in mice makes them resilient to stress, enhances their cognition, protects neurons from stroke and head trauma, and lessens neurodegeneration.
While inhibitors of Cdk5 could offer potential therapeutic benefits and new ways to study basic brain function, previous first- and second-generation anti-Cdk5 compounds largely get blocked at the blood-brain barrier that restricts movement of solutes from the blood to the central nervous system’s extracellular fluid. To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases.
Bibb and colleagues now report details of their anti-Cdk5, brain-permeable compound, 25-106. They also show that systemic administration of 25-106 alters neurobehavior in mice, reducing anxiety-like behavior.
“As perhaps the first robust systemic inhibitor, 25-106 represents an exciting and expandable and translatable pharmacological tool to study the function of Cdk5 activity in wild-type animals,” said Bibb, a professor in the University of Alabama at Birmingham Department of Surgery. “Achieving systemic applicability may be considered a step forward toward the testing of Cdk5 inhibitors to treat neuropsychiatric and neurodegenerative diseases. This provides a promising landscape for future studies to assess the effects of brain-permeable Cdk5 inhibitors to combat stress, anxiety, depression, addiction, cancer and neurodegeneration.”
The study, “Systemic administration of a brain permeable Cdk5 inhibitor alters neurobehavior,” is published in the journal Frontiers in Pharmacology.
In the paper, researchers describe synthesis of the aminopyrazole-based inhibitor, and they used molecular modeling to show that 25-106 appears to occupy the same hydrophobic binding pocket as the well-established Cdk5 inhibitor roscovitine.
They showed that 25-106 inhibited Cdk5 activity in a dose-dependent manner in brain striatal slices ex vivo, and that it also penetrated the brain after systemic administration in mice to inhibit Cdk5 in vivo. They measured the pharmacokinetic and pharmacodynamic parameters of 25-106 in blood plasma and the brains of mice, and the off-target distribution of 25-106 in the liver and kidneys.
Mice given systemic 25-106 showed modulated neurobehavior in the open field maze test and the tail suspension test, anxiolytic changes that have previously been linked to Cdk5 knockout mice.
They found that 25-106 is a non-selective inhibitor of both Cdk5 and another cyclin-dependent kinase, Cdk2, but note that very low levels of Cdk2 are found in the brain. However, any off-target or toxic effects of systemic inhibition of Cdk2 by 25-106 remain unknown.
Original Article: Novel preclinical drug could have potential to combat depression, brain injury and cognitive disorders
More from: University of Alabama Birmingham | University of Nebraska Medical Center
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
25-106 compound
- M&M shifts to high gear with Rs 37K cr investments
Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).
- Auto major M&M shifts to high gear with Rs 37,000 crore investments
M&M and the auto division expect to generate sufficient operating cash to satisfy their capital investment needs, the company said at the earnings press conference on Thursday ...
- 2024 BMW X2 First Look: Second Time’s a Charm?
The second-generation BMW X2 gets a more sculpted, coupe-like look, more power, and more space.BMW has just revealed the latest BMW X2, the sporty coupe-like SUV that we've enjoyed (mostly) in its ...
- Want to retire early? Here's our step-by-step guide
Early retirement might seem like an unattainable dream, but there are some simple steps you can take to make it a reality.
- MapmyIndia Announces 35% Rise in Net Profit for Q4 FY24
MapmyIndia reports a 35.11% increase in net profit for Q4 FY24, reaching Rs 38.25 crore, with revenue growth and a positive future outlook.
Go deeper with Google Headlines on:
25-106 compound
[google_news title=”” keyword=”25-106 compound” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cdk5 inhibitors
- Pharmacogenomics and Therapeutic Strategies for Dementia
Table 3. Potential therapeutic strategies in Alzheimer's disease and dementia.
- Breast Cancer Hormone Therapy Side Effects? What Helps
Many people who’ve had breast cancer take medications – tamoxifen or aromatase inhibitors – to help prevent the cancer from coming back. Doctors prescribe them for people with “hormone ...
- Checkpoint Inhibitors: A New Hope for Cancer Treatment
3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.
- Targeting cancer with small molecule kinase inhibitors
Small-molecule kinase inhibitors are being intensively pursued as new anticancer therapeutics. To date, approximately 80 inhibitors have been advanced to some stage of clinical evaluation.
- What Are Proton Pump Inhibitors (PPIs), and Do They Have Side Effects?
Proton pump inhibitors (PPIs) reduce or inhibit the production of stomach acid, which relieves symptoms of acid reflux and gastroesophageal reflux disease (GERD). These medications are available ...
Go deeper with Google Headlines on:
Cdk5 inhibitors
[google_news title=”” keyword=”nano factory” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]